Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 15/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518945 | 0.79 | CNR1 (0.41) | RAB9ASMN1; SMN2CNR1 | |
| SCHEMBL21555711 | 0.78 | ADORA2A (0.36) | NPC1RAB9ACNR1GGPS1FDPS | |
| SCHEMBL12970517 | 0.78 | GRM2 (0.51) | PRPS1GRM2NPC1MAPTNFKB1 | |
| SCHEMBL4855166 | 0.74 | CYP11B1 (0.58) | GRM2SMN1; SMN2 | |
| SCHEMBL31748263 | 0.73 | TDP1 (0.63) | MAPTSMN1; SMN2GGPS1FDPS | |
| SCHEMBL23851592 | 0.72 | PRPS1 (0.46) | PRPS1GRM2FDPS | |
| SCHEMBL31203106 | 0.71 | POLB (0.37) | PRPS1NPC1RAB9ACNR1GGPS1 | |
| SCHEMBL31641849 | 0.71 | PRPS1 (0.46) | PRPS1NPC1RAB9ACNR1GGPS1 | |
| SCHEMBL29535616 | 0.70 | GRM2 (0.41) | PRPS1GRM2 | |
| SCHEMBL900261 | 0.69 | GRM2 (0.46) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| US-20220040184-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP DOHME CORP. (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3883576-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | PRPS1 619/4885GRM2 634/4885NPC1 2870/4885 |
| US-20220040184-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2B, ADORA2A, ADORA3 | PRPS1 619/4885GRM2 634/4885NPC1 2870/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | PRPS1 682/4885GRM2 451/4885NPC1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.